Target type: biologicalprocess
Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of lipids. [GOC:ai]
Regulation of lipid catabolic process is a complex and tightly controlled process that ensures the proper breakdown and utilization of lipids to meet the energy demands of the cell. It involves a coordinated interplay of enzymes, hormones, and transcription factors, ensuring a balance between lipid storage and mobilization.
**1. Hormonal Regulation:**
* **Insulin:** Suppresses lipid catabolism by inhibiting the activity of hormone-sensitive lipase (HSL), the key enzyme responsible for breaking down triglycerides stored in adipocytes. Insulin promotes glucose uptake and utilization, reducing the need for lipid breakdown.
* **Glucagon:** Stimulates lipid catabolism by activating HSL, leading to the release of free fatty acids (FFAs) from adipocytes. This is particularly important during fasting or periods of low blood glucose, providing energy for tissues.
* **Adrenaline (epinephrine):** In response to stress or exercise, adrenaline stimulates lipid catabolism by activating HSL, providing a rapid source of energy.
**2. Enzyme Activation and Inhibition:**
* **Hormone-sensitive lipase (HSL):** This enzyme hydrolyzes triglycerides into FFAs and glycerol, making them available for energy production. It is activated by glucagon, adrenaline, and inhibited by insulin.
* **Carnitine palmitoyltransferase (CPT):** This enzyme facilitates the transport of long-chain fatty acids from the cytoplasm into the mitochondria, where they undergo beta-oxidation. It is inhibited by malonyl-CoA, a product of fatty acid synthesis.
* **Lipoprotein lipase (LPL):** This enzyme breaks down triglycerides within lipoprotein particles in the blood, allowing FFAs to be taken up by various tissues. It is regulated by insulin, glucagon, and other hormones.
**3. Transcriptional Regulation:**
* **Peroxisome proliferator-activated receptors (PPARs):** These nuclear receptors regulate gene expression involved in lipid metabolism. PPARĪ±, for example, promotes the expression of genes involved in fatty acid oxidation, while PPARĪ³ promotes adipogenesis.
* **Sterol regulatory element-binding proteins (SREBPs):** These transcription factors regulate the expression of genes involved in cholesterol and fatty acid synthesis. SREBP1c, in particular, is activated by insulin and promotes the synthesis of fatty acids.
**4. Intracellular Signaling Pathways:**
* **AMP-activated protein kinase (AMPK):** This kinase is activated during energy stress and promotes fatty acid oxidation by activating CPT1 and inhibiting acetyl-CoA carboxylase, an enzyme involved in fatty acid synthesis.
* **mTOR pathway:** This pathway is activated by nutrients and growth factors and promotes protein synthesis and lipid storage. It can be inhibited by AMPK.
**5. Feedback Mechanisms:**
* **Fatty acid levels:** High levels of FFAs in the blood inhibit HSL activity, preventing further breakdown of triglycerides.
* **Ketone bodies:** During prolonged fasting, the liver produces ketone bodies from fatty acids, which can be used as an energy source by tissues. Ketone bodies can also inhibit HSL activity, providing a negative feedback mechanism.
**6. Regulation in Different Tissues:**
* **Adipose tissue:** Primarily involved in lipid storage and release, regulated by insulin, glucagon, and adrenaline.
* **Liver:** Plays a central role in lipid metabolism, converting FFAs into ketone bodies during prolonged fasting.
* **Muscle:** Utilizes fatty acids as an energy source, particularly during prolonged exercise.
The regulation of lipid catabolic process is essential for maintaining energy homeostasis, ensuring a balance between energy storage and utilization, and preventing the accumulation of harmful lipids. Dysregulation of this process can lead to various metabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease.
'"
Protein | Definition | Taxonomy |
---|---|---|
NAD-dependent protein deacetylase sirtuin-6 | An NAD-dependent protein deacylase sirtuin-6 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N6T7] | Homo sapiens (human) |
Thyroid hormone receptor alpha | A thyroid hormone receptor alpha that is encoded in the genome of human. [PRO:HJD, UniProtKB:P10827] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
niacinamide | nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. | pyridine alkaloid; pyridinecarboxamide; vitamin B3 | anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor |
pyrazinamide | pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. | monocarboxylic acid amide; N-acylammonia; pyrazines | antitubercular agent; prodrug |
pyrazinoic acid | pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide. pyrazinoic acid: active metabolite of pyrazinamide; structure | pyrazinecarboxylic acid | antitubercular agent; drug metabolite |
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
3,3',5-triiodothyroacetic acid | tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome. | ||
3,3',5-triiodothyropropionic acid | aromatic ether | ||
thyroxine | thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions. Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. | 2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine; thyroxine zwitterion | antithyroid drug; human metabolite; mouse metabolite; thyroid hormone |
triiodothyronine | 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. | 2-halophenol; amino acid zwitterion; iodophenol; iodothyronine | human metabolite; mouse metabolite; thyroid hormone |
mifepristone | Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME. | 3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound | abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive |
tetraiodothyroacetic acid | 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'. tetraiodothyroacetic acid: RN given refers to parent cpd; structure | 2-halophenol; aromatic ether; iodophenol; monocarboxylic acid | apoptosis inducer; human metabolite; thyroid hormone |
1-(4-nitrophenyl)piperazine | 1-(4-nitrophenyl)piperazine: structure in first source | ||
3,5-dimethyl-3'-isopropyl-l-thyronine | 3,5-dimethyl-3'-isopropyl-L-thyronine: RN given refers to (L)-isomer | ||
rubimaillin | rubimaillin : A benzochromene that is 2H-benzo[h]chromene which is substituted by two methyl groups at position 2, a methoxycarbonyl group at position 5, and a hydroxy group at position 6. Found in the Chinese medical plant Rubia cordifola, It has an anti-cancer effect by inhibition of TNF-alpha-induced NF-kappaB activation. It is also a dual inhibitor of acyl-CoA:cholesterol acyltransferase 1 and 2 (ACAT1 and ACAT2), but is more selective for the ACAT2 isozyme. rubimaillin: structure given in first source | benzochromene; methyl ester; phenols | acyl-CoA:cholesterol acyltransferase 2 inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; neuroprotective agent; NF-kappaB inhibitor; plant metabolite |
5-chloropyrazinamide | |||
trichostatin a | trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES | antibiotic antifungal agent; hydroxamic acid; trichostatin | bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector |
(3R,5S)-fluvastatin | (3R,5S)-fluvastatin : A (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid diastereoisomer in which the stereocentres beta- and delta- to the carboxy group have R and S configuration, respectively. The drug fluvastatin is an equimolar mixture of this compound and its enantiomer. | (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; statin (synthetic) | |
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
gc 1 compound | GC 1 compound: structure in first source | diarylmethane | |
kb 141 | KB 141: an anticholesteremic agent; structure in first source | ||
kb 130015 | KB 130015: structure in first source | ||
cgs 23425 | CGS 23425: structure given in first source | ||
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid | 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid: a thyroid receptor beta1 agonist; structure in first source | ||
kb 2115 | 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid: a thyroid hormone receptor agonist with anticholesteremic activity | ||
fg-4592 | roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH). roxadustat: structure in first source | aromatic ether; isoquinolines; N-acylglycine | EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor |
mgl-3196 | resmetirom: a thyroid hormone receptor-beta agonist | ||
ly2784544 | pyridazines |